Analysis of hundreds of thousands of patient records showed differing risks for autoimmune disorders for new users of the more recent types of antidiabetic medications. @jeffsparks.bsky.social https://www.medpagetoday.com/rheumatology/generalrheumatology/122130

From @acr-journals.bsky.social Patients with systemic #autoimmune #RheumaticDiseases are more likely to exhibit prolonged #SARSCoV2 antigen positivity months after a #COVID19 infection compared with the general population. @mgbresearch.bsky.social @msjulieslam.bsky.social @jeffsparks.bsky.social#autoimmune

NEW RESEARCH—Trends in autoimmune rheumatic disease diagnoses before and after the COVID-19 pandemic in England: a population-based cohort study using @OpenSAFELY bit.ly/4p6WELY Plus linked Comment by @jeffsparks.bsky.social bit.ly/446onmh

The EULAR Social Media in #Rheumatology (SoMeR) Study Group is dedicated to exploring the role of social media in advancing scientific exchange and #education in rheumatology. We would be grateful if you could spare two minutes of your precious time to share your views: forms.gle/qZn7pKwDjwiU...

2-minute SURVEY for rheumatologists and healthcare professionals: As part of a Delphi exercise, the EULAR SoMer group aims to capture perspectives on priorities for Social Media use. We would be grateful if you could spare 2 minutes of your time to share your views: forms.gle/qZn7pKwDjwiU...

SARS-CoV-2 antigen positivity at months 3 and 6 following infection may be more common in rheumatic diseases than in the general population, driven largely by nucleocapsid antigen positivity Arthritis & Rheumatology doi.org/10.1002/art....

Your weekly recap of this week in Arthritis & Rheumatology SARS‐CoV‐2 antigen persistence in people with systemic autoimmune rheumatic diseases doi.org/10.1002/art.... Higher complement C4 gene copy number as risk factor for GCA and IgA vasculitis doi.org/10.1002/art....

How should clinicians approach psoriasis & psoriatic arthritis triggered by immune checkpoint inhibitors? This NEW episode reviews epidemiology, patient characteristics, & outcomes from a multicenter study of apremilast. 🎙️ LISTEN → acr.tw/4d6xoRs

Expert Review Screening for Rheumatoid Arthritis–Associated Interstitial Lung Disease: Current Evidence and Next Steps Needed for Routine Clinical Use 📖 doi.org/10.3899/jrhe... @jeffsparks.bsky.social @harvardmed.bsky.social #RheumatoidArthritis #InterstitialLungDisease

Incredibly exciting to be hosting our NIH P30-funded VERITY/Brigham Course in Rheumatology Clinical Research this week! 23 early investigators attending in person here in Boston to hone their grants and analyses. Another 50+ online attendees for the didactic portion Grateful for this community!

Target trial emulation: biologics or JAK vs RTX in RA-ILD -- abatacept (n=694), JAKi (156), IL-6i (389), or TNFi (734), PS-matched =# RTX; no significant differences (HR 0.74-1.09 NS) in outcomes of resp hosp, lung transplant & death. ABA & JAKi had less death www.sciencedirect.com/science/arti...

Phase 3b TOGETHER-PsA trial of ixekizumab + tirzepatide in comorbid overweight or obese adults with psoriatic arthritis showed clinically meaningful improvement of psoriatic disease, physical function, weight reduction, and quality-of-life, with no new safety concerns A&R doi.org/10.1002/art....

Head over to 👇 tourneytopia.com/AJKD/NephMad... and submit your #NephMadness Bracket

In patients with SLE without advanced lupus nephritis, obinutuzumab plus standard therapy was superior to placebo plus standard therapy in conferring and sustaining a clinically meaningful reduction in disease activity over 52 weeks. Full phase 3 ALLEGORY trial results: nej.md/4smEuWW #MedSky

Editor’s Picks Spotlight Investigating Factors Associated With RSV Vaccination and Breakthrough Infection Among Patients With SARDs 📖 www.jrheum.org/cgi/content/... @jeffsparks.bsky.social 📽️ Watch the video interview youtu.be/GnAghCae-hY #RSV #Vaccination

Earlier and more frequent immune suppression is used in scleroderma-associated ILD (from EUSTAR data) but there are still care gaps with still significant mortality in SSc-ILD and lack of prediction regarding who will progress Editorial in A&R @jeffsparks.bsky.social

Research Article Investigating Factors Associated With Respiratory Syncytial Virus Vaccination and Breakthrough Infection Among Patients With Systemic Autoimmune Rheumatic Diseases 📖 www.jrheum.org/cgi/content/... @jeffsparks.bsky.social #RSV #Vaccination

Very happy to share our latest paper about the current state and next steps needed to make screening for ILD in some subgroups of patients with RA. Lots to weigh for pros and cons, and more research work in progress. Thanks to our team and Lauren O'Keeffe for leading www.jrheum.org/content/earl...

Randomized phase 2 trial of pirfenidone (PFD) or placebo along with MMF in SSc-ILD ACR Open Rheumatology doi.org/10.1002/acr2... key findings ↓

ATTENTION all early investigators: FREE 2026 VERITY/Brigham Course in Rheum Clinical Research will be held in Boston on Apr 7-10, 2026 Hone your research/grant/career with Brigham and Women's Hospital and Harvard faculty. Funded by NIAMS Apply here by Dec 16: www.verityresearch.org/verity-cours...

Excited to share the results of the TeMPO (Treatment of Meniscal Problems in Osteoarthritis) trial, published today in NEJM: www.nejm.org/doi/full/10.... A labor of love from the #BWH #oracore team, with partners in Buffalo, Pittsburgh, and Cleveland. 879 randomized with the COVID in the middle!

In a cohort of patients screened for lung cancer with low-dose CT, patients with rheumatoid arthritis had higher prevalence of 'positive screen', fibrotic lung changes, & bronchiectasis. About 1 in 4 had a positive screen; 1 in 20 had lung cancer AC&R doi.org/10.1002/acr.... #Medsky #Oncsky

In a cohort of pts receiving CAR T cell therapy for hematologic cancer, pre-existing autoimmune disease was not associated with increase in major toxicity. Findings offer reassurance for CAR T cell cancer treatment in pts with pre-existing autoimmunity ACR Open Rheumatology doi.org/10.1002/acr2...

Abs 2662 McDermott @jeffsparks.bsky.social 🔎 Target trial emulation to address the Q of whether guidelines like ACR and CHEST are appropriate for conditionally recommending RTX over other biologics for RA-ILD? 📊 Data source: Medicare 👨‍👨‍👦 Study pop: RA ILD #ACR25

NEW RESEARCH—Risk factors for interstitial lung disease in early rheumatoid arthritis and external validation of screening strategies: a cross-sectional analysis of the prospective SAIL-RA cohort in the USA bit.ly/3L1F0t5 @jeffsparks.bsky.social

Excited to share the baseline results of our SAIL-RA cohort investigating lung health in early rheumatoid arthritis. Prevalence of ILD in early RA (median duration 8 months) was 11%. Strong associations with age and moderate/high RA activitity linkinghub.elsevier.com/retrieve/pii/S2665991325001584

Obinituzumab aka ‘Obi’ is now FDA approved for lupus nephritis finance.yahoo.com/news/fda-app... #lupus

🆕 Collaboration with RheumNow 🔵 3-Part Series on Interstitial Lung Disease Part 2: Diagnosis & Subtypes of #ILD 👩🏻‍⚕️ What to look for on Physical Exam 🧪 Serologic Testing & Diagnostic Workup 🫁 Differentiating ILD Subtypes on Imaging #RheumSky #PulmSky #MedSky #InterstitialLungDisease

Happy to have compiled this review on the role of the intestinal mucosa in RA and SpA with my friends @kknoop.bsky.social‬, Joyce, Mario, and Kentaro. We challenge the "leaky gut" hypothesis and why we shouldn't use that term that oversimplifies how our microbiome shapes immunity.

Alu expression in dermatomyositis muscle tissue doi.org/10.1002/art.... Characterizing a cohort of patients with SpA spectrum disorders initially presenting as PMR doi.org/10.1002/art.... Patients with RA-associated lung disease at increased risk of serious infection doi.org/10.1002/art.... ↓

New content online:

ICYMI in our May issue—Survival in patients with rheumatoid #arthritis and recently diagnosed early-stage colorectal, lung, or prostate #cancer receiving TNF inhibitors bit.ly/3Q9Or8N Plus, linked Comment by @jeffsparks.bsky.social & @nasingh.bsky.social bit.ly/42XQnsw #Medsky #Rheumsky

EULAR/American College of Rheumatology Risk Stratification Criteria for Development of Rheumatoid Arthritis in the Risk Stage of Arthralgia doi.org/10.1002/art.... Published simultaneously in Annals of Rheumatic Diseases #Medsky #Rheumsky

⏰ It’s Today! 3:15, Charter 3 🗣️ BSR SARD-ILD Guidelines working group! 👋🏽 me - management 👋🏽 Muhammad Nisar - monitoring 👋🏽 Nazia Chaudari - screening 🪑 Clive Kelly @cliveryton Come join us!! #ILD 🫁 🖐️!! #BSR2025

Thank you to the #NephMadness Selection Committee members who helped us develop the teams in each region: - @jordybc.bsky.social - Mehmet Sever - @thenestor.bsky.social - @jeffsparks.bsky.social - Mariana Murea - @lawdishu.bsky.social - Swee-Ling Levea - Babak Orandi - Susan Samuel

#NephMadness 2025 Champion: CAR-T for Autoimmune Diseases bit.ly/NM25Champ @nephrosparks.bsky.social @annaburgner.bsky.social @kidneywars.bsky.social @jrkott27.bsky.social @catochita.bsky.social

The final results of #RheumMadness 2025 are out! Read more about the panel's choices on our website, plus our list of thank you-s to all our collaborators who make this possible! sites.duke.edu/rheummadness/ Thank you all for another great year!

Research Article Serum Biomarkers of Pulmonary Damage and Risk for Progression of Rheumatoid Arthritis–Associated Interstitial Lung Disease 📖 www.jrheum.org/cgi/content/... @jeffsparks.bsky.social #biologicalmarkers #rheumatoidarthritis #interstitiallungdisease

Never played #RheumMadness ? Think you don't have enough time to submit your bracket? Think again. Submit with two simple steps: 1. Watch the 2-minute explainer video below 2. Head over to the tournament website and submit a bracket (IT'S FREE) 26.5 hours left! tourneytopia.com/RheumMadness...

Only 1.5 days left to submit your #RheumMadness bracket! Next up on our countdown: SGCAPS + MSKUS prediction tool for #giantcellarteritis, by fellows from MCW. Read it here: sites.duke.edu/rheummadness...

Incredible honor to participate in this year's #NephMadness- the tournament my brother @nephrosparks.bsky.social helped found years ago My commentary about basketball (#Razorbacks), brotherhood, and RheumOnc / CAR-T Also make sure to participate in #RheumMadness- CAR-T team there too

#NephMadness 2025: CAR-T for Autoimmunity – Driving to the Championship Any my brother getting involved this year !!!! @jeffsparks.bsky.social ajkdblog.org/2025/03/21/n...

#NephMadness 2025: CAR-T for Autoimmunity – Driving to the Championship Awesome to have the Sparks brothers in Nephmadness! @nephrosparks.bsky.social @jeffsparks.bsky.social ajkdblog.org/2025/03/21/n...

#NephMadness 2025 Commentary by @jeffsparks.bsky.social: CAR-T for Autoimmunity – Driving to the Championship bit.ly/NM25SparksCo...

Patients with systemic autoimmune rheumatic diseases remain at risk for hospitalisation for COVID-19 infection in the Omicron era (2022–2024): a retrospective cohort study rmdopen.bmj.com/content/11/1...

#RheumMadness + #NephMadness podcast is up! CAR-T discussion starts at min 22:30 Find it here 👇 rheummadness.buzzsprout.com/1465681/epis... @jeffsparks.bsky.social @nephmadness.bsky.social

#NephMadness 2025: The PodCrawl buff.ly/p3xR3cg Podcasts: - @thecurbsiders.bsky.social - Life as a Nephrology Professional @nkf-professionals.bsky.social - GN in Ten - @rheummadness.bsky.social - @freelyfiltered.bsky.social - Poison Lab - Nephron Segment - Kidney Chronicles

#NephMadness 2025: CAR-T for Kidney Disease Region buff.ly/iEgImMW Teams: - CAR-T for Autoimmune Disease - CAR-T Side Effects Expert: @jeffsparks.bsky.social Writer: Yara Mouawad Execs: Dia Waguespack & @annaburgner.bsky.social